Loading
A phase 2 trial of SYS6010 in head and neck squamous cell carcinoma, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07254585 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 70 participants planned, started 2025-12-18 and due to reach its primary completion in 2026-06-30. Interventions recorded: SYS6010 injection, Enlonstobart injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares SYS6010, CSPC Pharmaceutical Group.
Shares SYS6010, CSPC Pharmaceutical Group.
Shares SYS6010, CSPC Pharmaceutical Group.
Shares SYS6010, CSPC Pharmaceutical Group.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares SYS6010, CSPC Pharmaceutical Group.